|Day Low/High||117.00 / 121.59|
|52 Wk Low/High||29.51 / 94.01|
U.S. stocks closed higher Monday as oil prices gained steam and Wall Street looked ahead to the start of earnings season.
U.S. stocks are higher Monday thanks to a rally in crude oil.
Drug trial results dominate the market's biggest movers, while Twilio announces a secondary offering.
Tesaro is soaring, but the company is overvalued if regulators decide to grant marketing clearance for niraparib only in a smaller, more restricted population of ovarian cancer patients.
Tesaro's (TSRO) stock rating was lifted to 'buy' at Bank of America/Merrill Lynch.
Those who thought we were ready to break down look foolish again.
Here are Monday's top research calls, including upgrades for American Eagle, Mattel and Tesaro, and new coverage of Netflix.
Tesaro expects to file a new drug application before the end of the year for niraparib as a maintenance therapy for ovarian cancer.
A cancer research meeting beginning on Friday will provide investors with an opportunity to inspect updated clinical data on two competing PARP inhibitors from Clovis Oncology and Tesaro.
S&P closes near the lows of the day as momentum names get hit.
Tesaro (TSRO) stock closed higher in Monday's trading session after Pfizer (PFE) agreed to pay $14 billion for Medivation (MDVN).
Shareholders of the oncology drug maker ought to be satisfied with the auction's conclusion.
Overall, this is still a good environment for stock picking.
Acquiring Medivation will strengthen Pfizer's oncology franchise, which has lost ground in recent years to some Big Pharma competitors.
Bears continue to have a tough time gaining traction.
There is hesitancy to chase, especially with the FOMC rate decision this afternoon.